| Zhang, Jing |
NCT05536726: A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis |
|
|
| Recruiting | 3 | 450 | RoW | 608 Q2W, 608 Q4W, Placebo, PBO | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Psoriasis | 07/23 | 06/24 | | |
| Not yet recruiting | 3 | 136 | RoW | aerosol inhaled Amikacin Sulfate Injection, Aerosol Inhaled investigation drug, conventional therapy, Comparison Group | Shanghai Zhongshan Hospital | COPD, COPD Exacerbation | 12/23 | 12/23 | | |
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure |
|
|
| Recruiting | 3 | 522 | RoW | D-1553 Tablet, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 10/26 | 12/27 | | |
ReNEW, NCT06373731: Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD) |
|
|
| Recruiting | 3 | 360 | Europe, US, RoW | Elamipretide, Elamipretide HCL, Placebo | Stealth BioTherapeutics Inc. | Age Related Macular Degeneration (ARMD) | 08/26 | 08/27 | | |
| Recruiting | 3 | 360 | RoW | ZX-7101A, Placebo | Nanjing Zenshine Pharmaceuticals | Respiratory Viral Infection | 01/25 | 03/25 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Recruiting | 3 | 438 | Europe, Canada, US, RoW | N-acetylcysteine, Placebo | Johns Hopkins University, National Eye Institute (NEI), Duke University, Emory University, Massachusetts Eye and Ear Infirmary, Mayo Clinic, Medical College of Wisconsin, Retina Foundation of the Southwest, Stanford University, University of California, Davis, University of Florida, University of Iowa, University of Miami, University of Michigan, University of Minnesota, University of Oklahoma, University of Southern California, University of Utah, University of Washington, University of Wisconsin, Madison, Vanderbilt University, Vitreo Retinal Associates, PA, University of Houston, Medical University of Graz, McGill University, Universität Tübingen, Centro Medico ABC, Radboud University Medical Center, University of Amsterdam, University Hospital, Basel, Switzerland, University College London Hospitals, Northwestern University, University of Pennsylvania | Retinitis Pigmentosa | 12/28 | 12/28 | | |
NCT06569524: Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH) |
|
|
| Recruiting | 2 | 120 | RoW | TQA2225/AP025 or TQA2225/AP025 Placebo 25mg, TQA2225/AP025 or TQA2225/AP025 Placebo 50mg | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Non-alcoholic Steatohepatitis | 12/26 | 12/27 | | |
| Recruiting | 2 | 168 | RoW | Propranolol Hydrochloride, control group | Beijing Tiantan Hospital | Stroke, Vascular Accident, Intracranial Hemorrhages, Intracerebral Hemorrhage, Hemorrhagic Stroke, Stroke, Acute | 07/24 | 07/25 | | |
| Recruiting | 2 | 140 | US | ALK-001, C20-D3-Retinyl Acetate, C20 Deuterated vitamin A, Placebo | Alkeus Pharmaceuticals, Inc. | Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related) | 12/24 | 03/25 | | |
NCT05328531: Clinical Study of Genakumab for Injection in Patients With Acute Gout |
|
|
| Active, not recruiting | 1/2 | 121 | RoW | Genakumab for Injection, Placebo for Genakumab for Injection | GeneScience Pharmaceuticals Co., Ltd., Huashan Hospital, Hainan General Hospital, Linyi People's Hospital, The Second Affiliated Hospital of Chongqing Medical University, Changhai Hospital, The First Affiliated Hospital with Nanjing Medical University, Shengjing Hospital, Affiliated Hospital of Nantong University | Acute Gout | 05/22 | 05/22 | | |
NCT06302374: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 in Chinese Healthy Adults |
|
|
| Completed | 1/2 | 202 | RoW | GR2001, Placebo, HTIG, Tetanus Toxoid | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Tetanus | 11/23 | 02/24 | | |
NCT04434482: IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer |
|
|
| Completed | 1/2 | 59 | US, RoW | IMP4297(senaparib), temozolomide | Impact Therapeutics, Inc. | Advanced Solid Tumours, Small Cell Lung Cancer | 04/24 | 04/24 | | |
NCT04361812: Comparison of Pharmacokinetics and Safety of HS632 and Xolair® With a Single Injection |
|
|
| Not yet recruiting | 1 | 60 | RoW | HS632, Recombinant anti IgE humanized monoclonal antibody 150mg, Omalizumab (Xolair®), Omalizumab 150mg | Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd | Similarity of Pharmacokinetics and Safety | 12/21 | 12/21 | | |
| Completed | 1 | 16 | RoW | ABSK021 with fed state, ABSK021 with fasted state | Abbisko Therapeutics Co, Ltd | Neoplasms | 08/22 | 05/23 | | |
NCT04880512: The Safety, Tolerability, and Pharmacokinetics of SYHX1901 Tablets in Chinese Healthy Subjects |
|
|
| Recruiting | 1 | 102 | RoW | SYHX 1901 tablets, Placebo | CSPC Ouyi Pharmaceutical Co., Ltd. | Healthy Subjects | 08/22 | 12/22 | | |
NCT05217732: Study to Assess the Safety, Tolerability and Pharmacokinetics of ZX-7101A and the Food Effect in Healthy Volunteers |
|
|
| Completed | 1 | 66 | RoW | ZX-7101A, Placebo | Nanjing Zenshine Pharmaceuticals | Safety Issues, Tolerance, Pharmacokinetics, Food Effect | 08/22 | 12/22 | | |
NCT05490316: A Study of IBI353 (Orismilast) in Chinese Healthy Adults |
|
|
| Completed | 1 | 20 | RoW | IBI353 (Orismilast), placebo | Innovent Biologics (Suzhou) Co. Ltd. | Healthy Subjects | 11/22 | 12/22 | | |
NCT04994912: First in Human Study of EI-001 Monoclonal Antibody in Healthy Volunteers |
|
|
| Recruiting | 1 | 36 | RoW | EI-001, Placebo | Elixiron Immunotherapeutics Limited | Healthy | 02/25 | 04/25 | | |
NCT05750355: Evaluate the Effect of TPN171H on the QT/QTc Interval in Healthy Volunteers |
|
|
| Completed | 1 | 32 | RoW | TPN171H 10 mg Group, TPN171H 10 mg, TPN171H 30 mg Group, TPN171H 30 mg, TPN171H 40 mg Group, TPN171H 40 mg, TPN171H 50 mg Group, TPN171H 50 mg | Vigonvita Life Sciences | Healthy Subjects | 12/22 | 12/22 | | |
NCT04146285: A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders |
|
|
| Recruiting | 1 | 15 | RoW | BAT4406F | Bio-Thera Solutions | Neuromyelitis Optica Spectrum Disorders | 03/23 | 06/23 | | |
NCT06033742: A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects |
|
|
| Completed | 1 | 84 | RoW | HS-10374 tablets, HS-10374-matched placebo tablets | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Psoriasis | 03/23 | 03/23 | | |
| Completed | 1 | 12 | RoW | Etripamil Nasal Spray 70mg, Placebo | Ji Xing Pharmaceuticals (Shanghai) Co., Ltd., Milestone Pharmaceuticals Inc. | Healthy Chinese Subjects | 03/23 | 03/23 | | |
NCT04534582: Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX14 Versus Prolia® in Healthy Male Subjects |
|
|
| Completed | 1 | 252 | RoW | HLX14, EU-Prolia®, US-Prolia®, CN-Prolia® | Shanghai Henlius Biotech | Healthy Male Volunteers | 09/23 | 09/23 | | |
NCT05694221: Drug Drug Interaction (DDI) Between Supaglutide and Digoxin or Metformin |
|
|
| Completed | 1 | 34 | RoW | Supaglutide injection, Diabegone, Digoxin, Digoxin Tablets, Metformin, Glucophage | Shanghai Yinnuo Pharmaceutical Technology Co., Ltd., Huashan Hospital | Healthy Volunteers | 06/23 | 08/23 | | |
NCT06089733: A Clinical Trial to Evaluate the Effect of Itraconazole and Rifampicin on ABSK021 |
|
|
| Completed | 1 | 32 | RoW | Part A ABSK201 and Itraconazole, Part A ABSK201 and Rifampicin | Abbisko Therapeutics Co, Ltd | Healthy Subjects | 08/23 | 09/23 | | |
NCT05932459: A Study to Evaluate the Bioavailability, Food Effect and Pharmacokinetics of Deuremidevir Hydrobromide for Suspension |
|
|
| Completed | 1 | 38 | RoW | Deuremidevir Hydrobromide for Suspension 100mg, VV116, Deuremidevir Hydrobromide for Suspension 300mg, Deuremidevir Hydrobromide for Suspension 25mg, Deuremidevir Hydrobromide tablets 100mg | Vigonvita Life Sciences | Healthy Subjects | 09/23 | 09/23 | | |
NCT06144710: SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus |
|
|
| Recruiting | 1 | 48 | RoW | SG301 SC Injection, SG301 SC Placebo | Hangzhou Sumgen Biotech Co., Ltd. | Systemic Lupus Erythematosus (SLE) | 05/25 | 10/25 | | |
NCT05907382: Safety, Tolerability of JMKX003002 in Phase 1 Study in Healthy Subjects |
|
|
| Recruiting | 1 | 80 | RoW | JMKX003002 will be administered orally, JMKX003002, Placebo in Cohorts 1 to 5, Matching placebo will be administered orally, Placebo in 2 Cohorts | Jemincare | Safety and Tolerability | 12/23 | 03/24 | | |
| Not yet recruiting | 1 | 37 | NA | SGB-9768, Placebo | Suzhou Sanegene Bio Inc. | Healthy Volunteer | 05/25 | 10/25 | | |
NCT06055777: Study of the Safety, Tolerability, and PK of SZEY-2108 Administered Intravenously to HVs in SAD and MAD Cohorts |
|
|
| Terminated | 1 | 64 | RoW | SZEY-2108 for injetion, Novel monocyclic β-lactam antibiotics, Placebo, 0.9% Sodium Chloride Injection | Suzhou Erye Pharmaceutical Co., Ltd. | Infections | 05/24 | 05/24 | | |
| Recruiting | 1 | 70 | RoW | JMKX003801, Placebo | Jemincare | Healthy | 05/25 | 06/25 | | |
NCT05843422: A First-in-Human Study of QY211 Gel in Adult Subjects |
|
|
| Recruiting | 1 | 56 | RoW | 0.1% QY211 Gel or placebo, 0.3% QY211 Gel or placebo, 0.8% QY211 Gel or placebo, 1.5% QY211 Gel or placebo | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. | Atopic Dermatitis | 10/24 | 10/24 | | |
| Completed | 1 | 24 | RoW | TAK-279, Placebo | Takeda | Healthy Volunteers | 07/24 | 08/24 | | |
| Recruiting | N/A | 2000 | Europe, Japan, US, RoW | DENEB, DENEB (DEtection of colorectal NEoplasias in Blood) | City of Hope Medical Center | Colorectal Cancer, Colorectal Neoplasms, Colorectal Polyp, Colorectal Adenocarcinoma, Colorectal Disorders, Colorectal Dysplasia, Colorectal Cancer Stage I, Colorectal Cancer Stage II, Colorectal Cancer Stage III, Colorectal Cancer Stage IV, Colorectal Neoplasms Malignant, Colorectal Serrated Adenocarcinoma, Colorectal Adenoma With Severe Dysplasia, Colorectal Adenoma With Mild Dysplasia, Colorectal Adenoma With Moderate Dysplasia, Colorectal Adenoma and Carcinoma 1, Colorectal Adenomatous Polyp, Colorectal Adenocarcinoma Metastatic in the Liver | 12/25 | 12/25 | | |
NCT04152967: New Designed ePTFE Valved Conduits for Surgical Reconstruction of Right-ventricular Outflow Tract |
|
|
| Recruiting | N/A | 200 | RoW | new-designed PTFE valved conduits, Bovine jugular vein valved conduits | Children's Hospital of Fudan University, Shanghai Zhongshan Hospital, Shanghai Children's Medical Center | Right Ventricular Outflow Tract Absent, Congenital Heart Disease, Pulmonary Valve Disorders | 12/21 | 11/22 | | |
NCT03959709: Pre-pectoral Versus Sub-pectoral Implant Placement in Immediate Breast Reconstruction |
|
|
| Recruiting | N/A | 56 | Canada | immediate acellular dermal matrix-assisted implant-based breast reconstruction with prepectoral implant placement., Immediate acellular dermal matrix-assisted implant-based breast reconstruction with subpectoral implant placement | Ottawa Hospital Research Institute | Mastectomy, Breast Cancer | 12/22 | 12/23 | | |
NCT05532345: Discrimination of DILI and AIH by Artificial Intelligence |
|
|
| Completed | N/A | 2583 | RoW | | Beijing Friendship Hospital | Drug-induced Liver Injury, Autoimmune Hepatitis | 05/23 | 05/23 | | |
NCT06206590: Analysis of Differential Proteins and Maternal Influencing Factors of Septic Shock in Neonates |
|
|
| Recruiting | N/A | 116 | RoW | Whole-proteomic assay | Guangdong Women and Children Hospital | Neonatal Disease | 09/25 | 12/25 | | |
NCT05782881: High Risk Population of Cardiovascular Disease in Hubei Province Screening and Intervention Program |
|
|
| Recruiting | N/A | 16000 | RoW | phone calls and encouraging patients' lifestyle change and medication adherence, Statin, Angiotensin-converting enzyme inhibitor, Angiotensin receptor neprilysin inhibitor, Glucagon-like peptide-1, Sodium-dependent glucose transporters 2 | Wuhan Union Hospital, China, Peking University First Hospital | Cardiovascular Diseases, Diabetes Mellitus, Type 2, Coronary Disease | 12/23 | 12/24 | | |
| Not yet recruiting | N/A | 1500 | RoW | adrenal venous sampling | Chinese Academy of Medical Sciences, Fuwai Hospital | Hyperaldosteronism | 12/26 | 12/26 | | |
NCT06364462: Precise Evaluation Criteria for Histological Regression of NASH Fibrosis |
|
|
| Not yet recruiting | N/A | 220 | NA | lifestyle intervention | Beijing Friendship Hospital | NASH, Liver Fibrosis | 03/27 | 04/27 | | |
NCT06773221: The Efficacy and Safety of Chiglitazar in Patients with MAFLD-related Cirrhosis |
|
|
| Not yet recruiting | N/A | 195 | RoW | Chiglitazar 64mg, Placebo | Beijing Friendship Hospital, Beijing Ditan Hospital, Peking University People's Hospital, Beijing YouAn Hospital | Metabolic Dysfunction Associated Fatty Liver Disease, Compensated Liver Cirrhosis | 01/28 | 06/28 | | |
NCT04963374: the Effectiveness of Different Risk Scales In Predicting VTE in Respiratory Inpatients |
|
|
| Completed | N/A | 100 | RoW | risk evolution scale | Peking University Third Hospital | Venous Thromboembolism | 12/22 | 12/22 | | |
| Mao, Wei |
| No trials found |
